

Clinical Application of Materia Medica in Thyroid Disorders: Correlating Remedy Keynotes with TSH, T3, T4 Levels

Dr. Vaibhav Vijaya Ravindra Mahajan,
MD Homoeopathy (H.M.M) , PG.Hom (London UK), FCHD MUHS
Nashik MH , Professor & HOD, Department of Community Medicine
CMD – Dr. Mahajan’s Homoeopathic & Ayurvedic Panchakarma Centre,
Nashik – 422005

Dr. Aarti Gorakhnath Kanchar,
BHMS, MD (Homoeopathy – Practice of Medicine)
Associate Professor, Department of Community Medicine

Dr Sarvesh Umakant Tiwari ,
MD Homoeopathy (Repertory) , Assistant Professor
Dept. of Human Physiology , Dhanvantari H.M.C. & R.C.
Nashik, 422009,

Abstract

Background: Thyroid disorders are among the most prevalent endocrine conditions globally. While conventional therapy normalizes biochemistry, residual symptoms and patient-reported outcomes often remain suboptimal. Individualized Homoeopathy—guided by Materia Medica—may complement endocrine regulation.

Objective: To evaluate clinical outcomes and biochemical changes (TSH, free T3, free T4) in patients with thyroid dysfunction managed with individualized Homoeopathic remedies, and to correlate improvements with Materia Medica keynotes.

Methods:

A 12-week, prospective, observational study in an ambulatory setting included adults with hypothyroidism or subclinical hyperthyroidism. Individualized remedies were selected from Materia Medica (*Calcarea carbonica*, *Lycopodium*, *Sepia*, *Natrum muriaticum*, *Iodum*, *Thyroidinum*, etc.) based on totality with emphasis on keynote alignment. Primary outcomes:

change in TSH, fT3, fT4. Secondary outcomes: Fatigue VAS (0–10), ThyPRO-39 global score, and clinical global impression (CGI-I). Paired tests analyzed within-group change ($\alpha=0.05$).

Results: N=56 (hypothyroid n=44; subclinical hyper n=12). Mean TSH fell from 8.21 ± 2.94 to 4.97 ± 2.41 mIU/L ($p < 0.001$). fT3 rose from 2.61 ± 0.42 to 2.89 ± 0.48 pg/mL ($p = 0.002$); fT4 rose from 0.86 ± 0.15 to 0.95 ± 0.17 ng/dL ($p = 0.004$). Fatigue VAS improved from 7.1 ± 1.3 to 3.9 ± 1.4 ($p < 0.001$); ThyPRO global scores improved by 28%. CGI-I showed “much/very much improved” in 64.3%. Remedies most associated with improvement: *Calcarea carbonica* (constitutional chilliness, perspiration, craving eggs; 32%), *Lycopodium* (evening aggravation, bloating, anticipatory anxiety; 20%), *Natrum muriaticum* (headache, salt craving, grief; 14%), *Sepia* (ptosis of energy, bearing-down; 11%), *Iodum* (hypermetabolic features; 7%), *Thyroidinum* (organ-remedy adjunct; 9%).

Conclusion: Individualized Homoeopathy—aligned to Materia Medica keynotes—was associated with symptomatic and biochemical improvement in thyroid dysfunction over 12 weeks. Findings support pragmatic integration and justify controlled trials.

Keywords: Homoeopathy, Materia Medica, Thyroid, TSH, T3, T4, Calcareo carbonica, Lycopodium, Thyroidinum.

1. Introduction

Thyroid disorders—particularly hypothyroidism and autoimmune thyroiditis—are a growing global public-health concern. Conventional levothyroxine (LT4) corrects biochemistry for many, yet a subset continue to report fatigue, weight concerns, mood and cognitive symptoms. Individualized Homoeopathy, anchored in Materia Medica and Organon principles (§§5, 6, 153), may address person-centred patterns underlying endocrine imbalance. This study prospectively evaluates biochemical and patient-reported outcomes in thyroid dysfunction managed with individualized remedies and examines the correlation between Materia Medica keynotes and clinical response.

2. Objectives

1. Assess change in TSH, fT3, fT4 after individualized Homoeopathy over 12 weeks.
2. Evaluate change in fatigue (VAS) and ThyPRO global score.
3. Correlate remedy keynotes from Materia Medica with clinical response patterns.

3. Methods

3.1 Design & Setting

Prospective, observational, single-centre study (community clinic), 12-week follow-up.

3.2 Participants

Inclusion: Adults 18–65 yrs; newly diagnosed primary hypothyroidism (TSH ≥ 6 mIU/L) or subclinical hyperthyroidism (TSH ≤ 0.3 with near-normal fT3/fT4); symptomatic; willing for follow-up and labs at baseline & week-12.

Exclusion: Pregnancy, unstable cardiac disease, severe psychiatric illness, recent dose change of LT4 (< 6 weeks), antithyroid drugs, or steroid/iodine exposure.

3.3 Intervention: Individualized Homoeopathy

Remedies prescribed by senior homoeopathic physician using totality with keynote emphasis (Kent, Clarke). Common prescriptions:

- **Calcareo carbonica**—chilly, perspiring, craving eggs; slow, fatigued; weight gain.
- **Lycopodium**—bloating, right-sided complaints, evening aggravation; anticipatory anxiety.
- **Natrum muriaticum**—headache, salt craving, silent grief, dryness.
- **Sepia**—bearing-down sensation, indifference, better exercise; hormonal fatigue.
- **Iodum**—restlessness, heat, emaciation despite hunger; hypermetabolic.
- **Thyroidinum**—organ remedy adjunct in sluggish metabolism. Potency typically 30C or 200C; LM used in sensitive or chronic cases (§270). Dose repetition individualized (§§246–248).

3.4 Outcomes

Primary: TSH (mIU/L), fT3 (pg/mL), fT4 (ng/dL).

Secondary: Fatigue VAS (0–10), ThyPRO-39 global score, CGI-I at week-12.

3.5 Statistical Analysis

Paired t-tests (or Wilcoxon) for within-group change; descriptive correlation of

keynote-remedy selection and response clusters. $\alpha=0.05$.

3.6 Ethics

Written informed consent obtained; Helsinki (2013) adhered. Observational protocol under clinic oversight; confidentiality maintained.

4. Results

Sample: N=56; mean age 36.8 ± 9.4 ; 79% female. Hypothyroid 44 (78.6%), subclinical hyper 12 (21.4%). 21% on stable LT4 dose ≥ 6 weeks; no antithyroid drugs.

4.1 Biochemical Outcomes (Baseline $\rightarrow$ Week-12; mean $\pm$ SD)

- **TSH:** $8.21 \pm 2.94 \rightarrow 4.97 \pm 2.41$ ($\Delta -3.24$; $p < 0.001$)
- **fT3:** $2.61 \pm 0.42 \rightarrow 2.89 \pm 0.48$ ($\Delta +0.28$; $p = 0.002$)
- **fT4:** $0.86 \pm 0.15 \rightarrow 0.95 \pm 0.17$ ($\Delta +0.09$; $p = 0.004$)

4.2 Patient-Reported Outcomes

- **FatigueVAS:** $7.1 \pm 1.3 \rightarrow 3.9 \pm 1.4$ ($p < 0.001$)
- **ThyPRO global:** mean 28% improvement
- **CGI-I:** 64.3% “much/very much improved”; 26.8% “minimally improved”; 8.9% “no change”.

4.3 Remedies & Response Patterns

Most frequent first remedies: *Calcarea carb* (32%), *Lycopodium* (20%), *Natrum mur* (14%), *Sepia* (11%), *Thyroidinum* (9%), *Iodum* (7%); others (7%)

Responders typically matched keynote clusters:

- *Calcarea*—chilly, sweat, slowness, craving eggs, fear of misfortune $\rightarrow$ better energy, hair fall reduced.
- *Lycopodium*—bloating, gas, evening slump, right-sided issues $\rightarrow$ better digestion, confidence.

- *Natrum mur*—salt craving, headache, dryness, grief $\rightarrow$ improved headaches, mood.
- *Sepia*—bearing-down fatigue, indifference $\rightarrow$ improved stamina & menses regularity.
- *Iodum* (hyper features)—reduced palpitations, heat intolerance, anxiety.
- *Thyroidinum* adjunct—metabolic push where constitutional remedy alone sluggish.

4.4 Safety

No serious adverse events. Two transient aggravations (mild anxiety surge with *Iodum*; transient headache with *Natrum mur*); resolved with placebo/adjusted repetition.

5. Case Vignettes

Case1(Hypothyroid, *Calcarea carbonica*):

Female 31, fatigue, cold intolerance, weight gain, perspiration on scalp, craving eggs; TSH 9.8, fT3 2.4, fT4 0.82. *Calcarea carb 200C* single dose; placebo; later LM for gentle repetition. At week-12: TSH 5.1, fT3 2.8, fT4 0.93; Fatigue VAS 8 $\rightarrow$ 4; hair fall reduced; confidence improved.

Case 2 (Subclinical hyper, *Iodum*):

Male 27, heat intolerance, restlessness, hunger with weight loss, anxiety; TSH 0.18, fT3 3.6, fT4 1.46. *Iodum 30C* in water, cautious repetition; lifestyle counsel. At week-12: TSH 0.42, fT3 3.2, fT4 1.31; palpitations and anxiety subsided; CGI-I “much improved”.

6. Discussion

This practice-based cohort suggests individualized Materia Medica-guided Homoeopathy may aid normalization of thyroid biochemistry and alleviate symptoms within 12 weeks. Improvements in TSH, fT3, fT4 paralleled classic keynote congruence—supporting the heuristic that strong keynote alignment enhances response

probability. The use of *Thyroidinum* as an organ remedy adjunct was associated with earlier metabolic activation when constitutionals were slow to act. Mechanistically, homeopathic modulation may influence neuro-endocrine-immune balance (vital force/homeostasis), with emerging literature indicating nanostructures in high dilutions and hormetic signaling. Pragmatically, integrating individualized Homeopathy with endocrinology can address residual fatigue, mood, and QoL domains often under-treated by monotherapy.

Limitations: Observational design; modest sample; partial co-medication (LT4) in subset; short follow-up. **Strengths:** Biochemical endpoints; standardized PROMs (ThyPRO, VAS); explicit Materia Medica linkage.

7. Conclusion

Individualized Homeopathic remedies—carefully matched to Materia Medica keynotes—were associated with meaningful improvements in thyroid biochemistry and symptoms over 12 weeks. Results justify multicentre controlled trials and hybrid care pathways with endocrinology.

8. Practical Prescribing Notes (Box)

- Verify constitutional keynote congruence; weight *generals* and *mentals* equally.
- Prefer gentle repetition (LM) in sensitive, chronic, or mixed pathology (§270).
- Re-assess after 4–6 weeks; avoid frequent switching unless clear non-response.
- Consider *Thyroidinum* adjunct when constitutional action is sluggish (short course).

9. Ethical Declaration

Written informed consent obtained. Data anonymized. Helsinki (2013) principles

followed. No external funding. No conflicts of interest.

10. References (APA 7th)

- Hahnemann, S. (1921). *Organon of Medicine* (6th ed.). Germany: Arnold (Eng. trans. commonly used).
- Kent, J. T. (1905). *Lectures on Homoeopathic Materia Medica*. New Delhi: B. Jain (reprints).
- Clarke, J. H. (1900–1902). *A Dictionary of Practical Materia Medica* (Vols. 1–3). London: Homeopathic Publishing Co.
- Bell, I. R., & Koithan, M. (2018). A model for homeopathic remedy effects: Low-dose nanoparticles, hormesis, and complexity. *Homeopathy*, 107(2), 45–54.
- ThyPRO reference (patient-reported outcomes in thyroid disease).
- Park, K. (2023). *Textbook of Preventive and Social Medicine* (27th ed.). Jabalpur: Banarsidas Bhanot.
- CCRH (2022). *Homoeopathy in Public Health and Clinical Research*. New Delhi: Ministry of AYUSH.
- Allen, T. F. (1874–1879). *The Encyclopedia of Pure Materia Medica* (Vols. 1–10). New York: Boericke & Tafel.
- Boericke, W. (1927). *Pocket Manual of Homœopathic Materia Medica & Repertory* (9th ed.). New Delhi: B. Jain Publishers (Latest Reprint).
- Clarke, J. H. (1900–1902). *A Dictionary of Practical Materia Medica* (Vols. 1–3). London: Homeopathic Publishing Co.
- Hahnemann, S. (1833). *Materia Medica Pura* (2nd ed., Vols. 1–6). Leipzig: Arnold.
- Hahnemann, S. (1921). *Chronic Diseases: Their Peculiar Nature and Their Homoeopathic Cure* (Vols. 1–5). (2nd enlarged edition).
- Kent, J. T. (1905). *Lectures on Homœopathic Materia Medica*. New Delhi: B. Jain Publishers.

- Nash, E. B. (1913). *Leaders in Homœopathic Therapeutics*. New Delhi: B. Jain Publishers.
- Phatak, S. R. (1977). *Materia Medica of Homoeopathic Medicines*. Mumbai: Kalindi Publishers.
- Boger, C. M. (1931). *Synoptic Key of the Materia Medica*. New Delhi: B. Jain Publishers.
- Farrington, E. A. (1887). *Clinical Materia Medica*. New Delhi: B. Jain Publishers.